Cassava Sciences Concludes DOJ Investigation into Research Misconduct
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Source: stocktwits
- DOJ Investigation Closure: Cassava Sciences announced that the U.S. Department of Justice has closed its investigation into research misconduct related to its drug Simufilam, indicating full cooperation during the probe, although the company's stock fell 2% at the time of the announcement.
- SEC Settlement Details: In September 2024, Cassava reached a settlement with the U.S. Securities and Exchange Commission, paying a monetary penalty without admitting or denying the allegations, which involved misleading statements about its Alzheimer's treatment, highlighting the company's vulnerability under regulatory scrutiny.
- New Drug Development Focus: Cassava has shifted its focus from developing Simufilam for Alzheimer's to treating tuberous sclerosis complex-related epilepsy, reflecting a strategic pivot in response to the drug's failure to demonstrate clinical benefits in late-stage trials.
- Market Sentiment Shift: On Stocktwits, retail sentiment around SAVA stock rose from 'neutral' to 'bullish' over the past 24 hours, despite a 25% decline in stock price over the past year, indicating cautious optimism among investors regarding the company's future.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
